骨髓增生异常综合征患者预后判断与风险分层的演变轨迹
Risk stratification and prognostication are crucial for the appropriate management of patients with myelodysplastic syndromes (MDSs) or myelodysplastic neoplasms, for whom the expected survival can vary from a few months to >10 years.…
要点
- MDS患者预期生存可从数月到超过10年不等,风险分层对治疗管理至关重要。
- 形态学发育异常、血液学参数、细胞遗传学及近期纳入的突变信息被整合进预后评分系统。
核心结论
- 预后评分系统的逐步演变和改进最终形成了当前的分子国际预后评分系统。
研究设计与样本
- 综述,描述MDS预后评分系统从临床参数到分子信息的逐步演变。
主要发现
- MDS患者预期生存可从数月到超过10年不等。
- 形态学发育异常、临床血液学参数、细胞遗传学及近期突变信息被纳入预后评分系统,以细化风险分层并指导治疗管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk stratification and prognostication are crucial for the appropriate management of patients with myelodysplastic syndromes (MDSs) or myelodysplastic neoplasms, for whom the expected survival can vary from a few months to >10 years. For the past 5 decades, patients with MDS have been classified into higher-risk vs lower-risk disease phenotypes using sequentially developed clinical prognostic scoring systems. Factors such as morphologic dysplasia, clinical hematologic parameters, cytogenetics, and, more recently, mutational information have been captured in prognostic scoring systems that refine risk stratification and guide therapeutic management in patients with MDS. This review describes the progressive evolution and improvement of these systems which has led to the current Molecular International Prognostic Scoring System.
引用
- DeZern AE, Greenberg PL. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes. Blood. 2023. PMID: 37562001. doi:10.1182/blood.2023020081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。